Tumor necrosis factor α is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1

Obesity is associated with a cluster of abnormalities, including hypertension, insulin resistance, hyperinsulinemia, and elevated levels of both plasminogen activator inhibitor 1 (PAI-1) and transforming growth factor β (TGF-β). Although these changes may increase the risk for accelerated atherosclerosis and fatal myocardial infarction, the underlying molecular mechanisms remain to be defined. Although tumor necrosis factor α (TNF-α) has been implicated in the insulin resistance associated with obesity, its role in other disorders of obesity is largely unknown. In this report, we show that in obese (ob/ob) mice, neutralization of TNF-α or deletion of both TNF receptors (TNFRs) results in significantly reduced levels of plasma PAI-1 antigen, plasma insulin, and adipose tissue PAI-1 and TGF-β mRNAs. Studies in which exogenous TNF-α was infused into lean mice lacking individual TNFRs indicate that TNF-α signaling of PAI-1 in adipose tissue can be mediated by either the p55 or the p75 TNFR. However, TNF-α signaling of TGF-β mRNA expression in adipose tissue is mediated exclusively via the p55 TNFR. Our results suggest that TNF-α is a common link between the insulin resistance and elevated PAI-1 and TGF-β in obesity. The chronic elevation of TNF-α in obesity thus may directly promote the development of the complex cardiovascular risk profile associated with this condition.

[1]  M. Cigolini,et al.  Expression of plasminogen activator inhibitor-1 in human adipose tissue: a role for TNF-alpha? , 1999, Atherosclerosis.

[2]  G. Hotamisligil,et al.  The role of TNF alpha in adipocyte metabolism. , 1999, Seminars in cell & developmental biology.

[3]  K. Uysal,et al.  Functional analysis of tumor necrosis factor (TNF) receptors in TNF-alpha-mediated insulin resistance in genetic obesity. , 1998, Endocrinology.

[4]  D. Loskutoff,et al.  Tissue factor gene expression in the adipose tissues of obese mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[5]  D. Loskutoff,et al.  The adipocyte and hemostatic balance in obesity: studies of PAI-1. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[6]  C. Fearns,et al.  Role of tumor necrosis factor alpha in induction of murine CD14 gene expression by lipopolysaccharide , 1997, Infection and immunity.

[7]  K. Uysal,et al.  Protection from obesity-induced insulin resistance in mice lacking TNF-α function , 1997, Nature.

[8]  Margaret S. Wu,et al.  Targeted Disruption of the Tumor Necrosis Factor-α Gene: Metabolic Consequences in Obese and Nonobese Mice , 1997, Diabetes.

[9]  M. Jensen,et al.  Obesity and cardiovascular disease: is body structure a factor? , 1997, Current opinion in lipidology.

[10]  M. Alessi,et al.  PAI-1, Obesity, Insulin Resistance and Risk of Cardiovascular Events , 1997, Thrombosis and Haemostasis.

[11]  Xing-li Wang,et al.  Circulating transforming growth factor β1 and coronary artery disease , 1997 .

[12]  P. Morange,et al.  Production of Plasminogen Activator Inhibitor 1 by Human Adipose Tissue: Possible Link Between Visceral Fat Accumulation and Vascular Disease , 1997, Diabetes.

[13]  P. Carmeliet,et al.  Molecular genetics of the fibrinolytic and coagulation systems in haemostasis, thrombogenesis, restenosis and atherosclerosis. , 1997, Current opinion in lipidology.

[14]  C. Fearns,et al.  Induction of plasminogen activator inhibitor 1 gene expression in murine liver by lipopolysaccharide. Cellular localization and role of endogenous tumor necrosis factor-alpha. , 1997, The American journal of pathology.

[15]  D. Loskutoff,et al.  Elevated Expression of Transforming Growth Factor-β in Adipose Tissue from Obese Mice , 1997 .

[16]  A. Prentice,et al.  Obesity--the inevitable penalty of civilisation? , 1997, British medical bulletin.

[17]  D. Loskutoff,et al.  Tissue Distribution and Regulation of Plasminogen Activator Inhibitor-1 in Obese Mice , 1996, Molecular medicine.

[18]  J. Harvey-Berino,et al.  Amelioration of the inhibition of fibrinolysis in elderly, obese subjects by moderate energy intake restriction. , 1996, The American journal of clinical nutrition.

[19]  S. Yamashita,et al.  Enhanced expression of PAI–1 in visceral fat: Possible contributor to vascular disease in obeisty , 1996, Nature Medicine.

[20]  D. Loskutoff,et al.  Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide. , 1996, The Journal of clinical investigation.

[21]  A. Pfeiffer,et al.  Diabetic microvascular complications and growth factors. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[22]  W. Fiers,et al.  Two tumour necrosis factor receptors: structure and function. , 1995, Trends in cell biology.

[23]  M. Lenardo,et al.  Induction of apoptosis in mature T cells by tumour necrosis factor , 1995, Nature.

[24]  R. Simsolo,et al.  The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. , 1995, The Journal of clinical investigation.

[25]  B. Spiegelman,et al.  Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. , 1995, The Journal of clinical investigation.

[26]  B. Beutler,et al.  How do tumor necrosis factor receptors work? , 1995, Journal of inflammation.

[27]  J. McGill,et al.  Factors Responsible for Impaired Fibrinolysis in Obese Subjects and NIDDM Patients , 1994, Diabetes.

[28]  W. Border,et al.  Transforming growth factor-beta and the pathogenesis of glomerular diseases. , 1994, Current opinion in nephrology and hypertension.

[29]  B. Spiegelman,et al.  Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance. , 1994, Endocrinology.

[30]  R. Derynck,et al.  Direct transfer of transforming growth factor beta 1 gene into arteries stimulates fibrocellular hyperplasia. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[31]  L. Tartaglia,et al.  Stimulation of human T-cell proliferation by specific activation of the 75-kDa tumor necrosis factor receptor. , 1993, Journal of immunology.

[32]  L. Tartaglia,et al.  A novel domain within the 55 kd TNF receptor signals cell death , 1993, Cell.

[33]  M. Blankenstein,et al.  The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. , 1993, Metabolism: clinical and experimental.

[34]  H. Loetscher,et al.  Tumor necrosis factor alpha (TNF-alpha)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55 , 1993, The Journal of experimental medicine.

[35]  Mike Rothe,et al.  Tumor necrosis factor's cytotoxic activity is signaled by the p55 TNF receptor , 1993, Cell.

[36]  B. Spiegelman,et al.  Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. , 1993, Science.

[37]  Y. Eguchi,et al.  Cellular localization of type 1 plasminogen activator inhibitor messenger RNA and protein in murine renal tissue. , 1993, The American journal of pathology.

[38]  L. Tartaglia,et al.  Antiviral activity of tumor necrosis factor is signaled through the 55-kDa type I TNF receptor [corrected]. , 1992, Journal of Immunology.

[39]  J. Primrose,et al.  Reduction in Factor VII, Fibrinogen and Plasminogen Activator Inhibitor-1 Activity after Surgical Treatment of Morbid Obesity , 1992, Thrombosis and Haemostasis.

[40]  W. Fiers,et al.  Functional characterization of the human tumor necrosis factor receptor p75 in a transfected rat/mouse T cell hybridoma , 1992, The Journal of experimental medicine.

[41]  L. Tartaglia,et al.  Two TNF receptors. , 1992, Immunology today.

[42]  P. Björntorp,et al.  Abdominal fat distribution and disease: an overview of epidemiological data. , 1992, Annals of medicine.

[43]  L. Tartaglia,et al.  The two different receptors for tumor necrosis factor mediate distinct cellular responses. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[44]  D. Loskutoff,et al.  Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. , 1991, The Journal of clinical investigation.

[45]  P. Vague,et al.  Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women. , 1989, Metabolism: clinical and experimental.

[46]  C. Legnani,et al.  Reduced fibrinolytic response in obese children: Association with high baseline activity of the fast acting plasminogen activator inhibitor (PAI-1) , 1988 .

[47]  C. Kluft,et al.  Plasminogen activator inhibitors. , 1987, Blood.

[48]  D. Loskutoff,et al.  Immunoradiometric assay to measure the binding of a specific inhibitor to tissue-type plasminogen activator. , 1985, The Journal of laboratory and clinical medicine.